Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03805438 · ClinicalTrials.gov registry record · Phase 4
ED90 of 3% Chloroprocaine for Cervical Cerclage
A Phase 4 study of Cerclage, Cervical, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
- 2
- Study locations
NCT03805438: Completed Phase 4 study of Cerclage, Cervical, sponsored by Duke University.
NCT03805438 is a Phase 4 study of Cerclage, Cervical that has completed, run by Duke University. The registered enrollment target is 47 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03805438, a Phase 4 study of Cerclage, Cervical, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
- 2
- Study locations
Study Summary
The aim of this study is to identify the dose of intrathecal (IT) chloroprocaine that provides effective anesthesia in 90% of patients undergoing elective cerclage placement (intraoperative analgesic supplementation not required).
Primary Outcome
Identification of the dose of intrathecal 3% chloroprocaine that will provide adequate anesthesia for a cervical cerclage to occur.
Conditions Studied
Interventions
- DRUG Chloroprocaine Hcl 3% Inj
Study Locations (2)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
North Carolina
- Duke University Hospital - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2020-10-23 |
| Phase | Phase 4 |
What the finished NCT03805438 record still lists
NCT03805438 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Cerclage, Cervical appearing as the primary indexed condition, and to 1 intervention - of which Chloroprocaine Hcl 3% Inj is the first listed.
NCT03805438 reports a single indexed study location in Arkansas, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03805438 about?
NCT03805438 is a clinical study titled "ED90 of 3% Chloroprocaine for Cervical Cerclage". The aim of this study is to identify the dose of intrathecal (IT) chloroprocaine that provides effective anesthesia in 90% of patients undergoing elective cerclage placement (intraoperative analgesic supplementation not required).
What is the current status of trial NCT03805438?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2019-02-07. Estimated completion is 2020-10-23.
What conditions does trial NCT03805438 study?
This clinical trial studies the following conditions: Cerclage, Cervical.
What interventions are being tested in trial NCT03805438?
The interventions under investigation include: Chloroprocaine Hcl 3% Inj (DRUG).
Who is sponsoring clinical trial NCT03805438?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03805438 being conducted?
This trial has 2 study locations across Arkansas, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03805438's enrollment target sits among peer trials
47 1348th of 2000 higher than 653 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI